NEW YORK--(BUSINESS WIRE)--Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest and most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., announced it has opened a new dispensary in Colonial Heights, Virginia, under its gLeaf brand. This is the Company’s eighth dispensary in the state, and 84th active dispensary nationwide. The dispensary is located at 401 Southpark Boulevard.
“As Virginians continue to normalize cannabis across the Commonwealth, we are thrilled to bring them another location where they can access their medicine,” said Phil Goldberg, VP, Operations, Columbia Care. “We are grateful to the Board of Pharmacy and our new neighbors who have graciously welcomed us to the Colonial Heights community.”
gLeaf Colonial Heights will sell Columbia Care products including gLeaf, Classix and Seed & Strain. Columbia Care and Green Leaf Medical (gLeaf) are licensed to operate a market-leading total of 12 dispensaries in Virginia combined. The Company plans to open another dispensary in the near term, pending regulatory approval. Columbia Care also has a fleet of delivery vehicles able to serve the entire state from its Richmond-area locations.
“We continue to be excited by the momentum building in Virginia, already one of our top markets, as we open additional locations and broaden access to this incredible plant,” said Jesse Channon, Chief Growth Officer, Columbia Care. “Our Virginia team is working hard to bring the highest quality product and the highest level of customer service to the patients we serve. We look forward to continued expansion of this burgeoning medical program.”
For more information, visit https://gleaf.com/colonial-heights-menu/.
About Columbia Care
Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 18 U.S. jurisdictions. Columbia Care operates 128 facilities including 95 dispensaries and 33 cultivation and manufacturing facilities, including those under development. Columbia Care is one of the original multi-state providers of medical cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the company launched Cannabist, its new retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber. For more information on Columbia Care, please visit www.columbia.care.
Caution Concerning Forward-Looking Statements
This press release contains certain statements that constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. Forward-looking statements or information contained in this release include, but are not limited to, statements or information with respect to the Company’s ability to execute on retail, wholesale, brand and product initiatives. These forward-looking statements or information, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. These risks, uncertainties and other factors include, among others, favorable operating and economic conditions; obtaining and maintaining all required licenses and permits; favorable production levels and sustainable costs from the Company’s operations; and the level of demand for cannabis products, including the Company’s products sold by third parties. In addition, securityholders should review the risk factors discussed under “Risk Factors” in Columbia Care’s Form 10 dated May 9, 2022, filed with the applicable securities regulatory authorities and described from time to time in documents filed by the Company with Canadian and U.S. securities regulatory authorities.
